Artículos de revistas
Outcomes Of Autologous Transplantation For Multiple Myeloma According To Different Induction Regimens
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. Sociedade Brasileira De Hematologia E Hemoterapia, v. 36, n. 1, p. 19 - 24, 2014.
15168484
10.5581/1516-8484.20140008
2-s2.0-84897760226
Autor
Crusoe E.Q.
Higashi F.
Padilha M.P.N.C.
Miranda E.C.M.
Quero A.A.
Almeida M.S.S.
Peres A.L.M.
Cury P.
Chiattone C.
Barros J.C.
Hungria V.T.M.
Institución
Resumen
Background: Induction therapy followed by high-dose chemotherapy and autologous transplantation is the standard treatment for suitable patients with multiple myeloma. Objective: The aim of this study was to assess whether induction therapy with thalidomide-containing regimens was associated with improved results compared to vincristine, doxorubicin, and dexamethasone, and whether cyclophosphamide, thalidomide, and dexamethasone were associated with better results than thalidomide and dexamethasone. Methods: The records of 152 patients who underwent autologous transplantation at this institution from August of 2004 to January of 2012 were reviewed, selecting those with at least partial response to a maximum of eight cycles of induction therapy and sufficient follow-up information for analysis. Results: This study included 89 patients; 44 were female, with a mean age of 55 years (there was a significant trend for increasing age over the years of the study). The median number of induction therapy cycles was four, again with a trend of increase over the years. At least a very good partial response to induction therapy was achieved more often in the cyclophosphamide, thalidomide, and dexamethasone group (61.1%) and in the thalidomide and dexamethasone group (59.2%) than in the vincristine, doxorubicin, and dexamethasone group (16.2%). The overall median progression-free survival was 34 months, with no statistically significant difference between the three groups. The overall median survival was not reached, and there was no significant difference between the three groups; the estimated five-year overall survival was 55%. Conclusion: Although the quality of responses appeared to be better with thalidomidecontaining regimens, these improvements did not translate into improved long-term outcomes. Given its track record, cyclophosphamide, thalidomide, and dexamethasone is currently considered the preferred regimen for first-line induction therapy in the Brazilian public health system. © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights reserved. 36 1 19 24 San, M.J.F., Blade, C.J., Garcia-Sanz, R., Treatment of multiple myeloma (1999) Haematologica, 84 (1), pp. 36-58 Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome (1996) N Engl J Med, 335 (24), pp. 1844-1845. , author reply 1845 Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma (2003) N Engl J Med, 348 (19), pp. 1875-1883 Bladé, J., Rosiñol, L., Sureda, A., Ribera, J.M., Díaz-Mediavilla, J., García-Laraña, J., Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA (2005) Blood, 106 (12), pp. 3755-3759 Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Antitumor activity of thalidomide in refractory multiple myeloma (1999) N Engl J Med, 341 (21), pp. 1565-1571. , Comment In: N Engl J Med. 2001;344(25):1951-2 N Engl J Med. 2000;343(13):972-3 N Engl J Med. 2000;342(13):975 author reply 975-6 N Engl J Med. 1999;341(21):1606-9 Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R., Greipp, P.R., Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group (2006) J Clin Oncol, 24 (3), pp. 431-436. , Comment in: J Clin Oncol. 2006;24(3):334-6 J Clin Oncol. 2006 24(18):2967-8 author reply 2968-9 Nat Clin Pract Oncol. 2008;5(12):690-1 Eastern Cooperative Oncology Group Rajkumar, S.V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma (2008) J Clin Oncol, 26 (13), pp. 2171-2177 Kumar, S., Giralt, S., Stadtmauer, E.A., Harousseau, J.L., Palumbo, A., Bensinger, W., Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens (2009) Blood, 114 (9), pp. 1729-1735. , International Myeloma Working Group Reece, D.E., An update of the management of multiple myeloma: The changing landscape (2005) Hematology Am Soc Hematol Educ Program, pp. 353-359 Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma (2005) Blood, 106 (1), pp. 35-39. , Bologna 2002 study Lokhorst, H.M., van der Holt, B., Zweegman, S., Vellenga, E., Croockewit, S., van Oers, M.H., A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma (2010) Blood, 115 (6), pp. 1113-1120. , Dutch-Belgian Hemato-Oncology Group (HOVON) Morgan, G.J., Davies, F.E., Gregory, W.M., Bell, S.E., Szubert, A.J., Navarro, C.N., Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results (2012) Haematologica, 97 (3), pp. 442-450. , National Cancer Research Institute Haematological Oncology Clinical Studies Group Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study (2010) Lancet, 376 (9758), pp. 2075-2085 Lopes, L.C., Barberato-Filho, S., Costa, A.C., Osorio-de-Castro, C.G., Rational use of anticancer drugs and patient lawsuits in the state of Sao Paulo, Southeastern Brazil (2010) Rev Saude Publica, 44 (4), pp. 620-628 (2012) ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US), , http://clinicaltrials.gov/show/NCT01532856, Feb 10-Identifier NCT01532856, Iberoamerican protocol with thalidomide in patients with symptomatic newly diagnosed multiple myeloma over 65 years. [cited 22 May 2013]. Available from (2011) ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US), , http://clinicaltrials.gov/show/NCT01532856, Jan 27-2011 Feb 14. Identifier NCT01296503, Thalidomide plus dexamethasone as maintenance therapy for multiple myeloma. [cited 22 May 2013]. Available from Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., International uniform response criteria for multiple myeloma (2006) Leukemia, 20 (9), pp. 1467-1473. , Comment in: Leukemia. 2006;20(9):1467-73 Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT (1998) Br J Haematol, 102 (5), pp. 1115-1123. , European Group for Blood and Marrow Transplant Wu, P., Davies, F.E., Horton, C., Jenner, M.W., Krishnan, B., Alvares, C.L., The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: A case-matched analysis (2006) Leuk Lymphoma, 47 (11), pp. 2335-2338